Ishihara, Hiroki
Nemoto, Yuki
Nakamura, Kazutaka
Tachibana, Hidekazu
Fukuda, Hironori
Yoshida, Kazuhiko
Kobayashi, Hirohito
Iizuka, Junpei
Shimmura, Hiroaki
Hashimoto, Yasunobu
Kondo, Tsunenori
Takagi, Toshio
Article History
Accepted: 25 November 2022
First Online: 26 December 2022
Declarations
:
: No external funding was used in the preparation of this article.
: Toshio Takagi received honoraria from BristolMyers Squibb and Ono Pharmaceutical. Tsunenori Kondo received honoraria from Pfizer, Novartis, Bristol-Myers Squibb, and Ono Pharmaceutical. Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, and Yasunobu Hashimoto have no conflicts of interest that are directly relevant to the content of this article.
: The study protocol was approved by the institutional ethics review board of each institution (Tokyo Women’s Medical University, Tokyo Women’s Medical University Adachi Medical Center, Saiseikai Kawaguchi General Hospital, Saiseikai Kazo Hospital, and Jyoban Hospital; ID: 2020-0009). The present study was performed according to the guidelines of the 1964 Declaration of Helsinki and its later amendments. Owing to the retrospective observational nature of this study, the need for informed consent was waived.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the study’s conception and design, data collection, and analysis. The first draft of the manuscript was written by HI and all authors commented on the previous drafts of the manuscript. All authors read and approved the final version of the manuscript.